Skip to main content

Sanofi

corporate_fare Company Profile

Sanofi

SNY·NASDAQ·Life Sciences·CIK 0001121404

Sanofi is a biopharmaceutical company focused on improving people's lives through its R&D-driven and AI-powered approach. The company's activities are organized within the Biopharma operating segment, which includes categories such as Immunology, Rare Diseases, Neurology, Oncology, Other Medicines, and Vaccines. Sanofi operates in a global market characterized by a growing and aging population with high unmet medical needs. The company emphasizes innovation in R&D and advanced manufacturing to launch new medicines and vaccines. It also leverages digital technologies and advanced data analytics across sales, marketing, R&D, and manufacturing. The pharmaceutical industry faces challenges including geopolitical uncertainties, inflation, supply shortages, and government budget tightening, which put pressure on healthcare costs. Payers are scrutinizing prices and reimbursement criteria, demanding real-life outcome demonstrations for efficacy. Sanofi aims to contribute to improved patient access and the development of innovative, cost-effective medicines.

Sanofi (NASDAQ:SNY) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 46 items for SNY at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Sanofi Reports Strong Q4/FY25 Sales & EPS, Guides Higher for 2026; Tolebrutinib Fails Phase 3
  • Sanofi Updates Dynavax Tender Offer with Regulatory Clearances and Shareholder Lawsuits
  • Amlitelimab Phase 3 Studies Show Mixed Results in Atopic Dermatitis, Sanofi Plans Global Submissions
  • Sanofi Secures EU Approval for Teizeild in Type 1 Diabetes, Plus Two China Approvals
  • Sanofi Commences Tender Offer to Acquire Dynavax Technologies for $15.50 Per Share in Cash

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
$7.85B
Diluted EPS
$6.37
Op. Cash Flow
$10.75B
Free Cash Flow
$7.21B
Gross Profit
$33.67B
Operating Income
$6.34B
Cash & Equivalents
$877M
Total Debt
$14.25B
Debt / Equity
0.20×
Shares Outstanding
1.22B sh
Source: 20-F · filed 2026-02-17 · accession 0001628280-26-008403

Insider Transactions

SNY files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

$40 +0.08% today
52-week range · as of 2026-09-17 $40 – $52.68
Market cap
$95.46B
Volume
4.3M (1.7× avg)
3-mo avg 2.6M
Live data · 2026-10-04 14:30 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed SNY - Filings & News (Page 3)

SNY
Jan 29, 2026, 8:56 AM EST
Filing Type: 6-K
Importance Score:
8
Sanofi Reports Strong Q4/FY25 Sales & EPS, Guides Higher for 2026; Tolebrutinib Fails Phase 3
Price at Filing: $46.52
Real-time Price: $40.00 info
Change: -$6.52 (-14%) info
Market Cap: $95.459B info
Sentiment: Neutral
View Wiseek Article
SNY
Jan 28, 2026, 6:37 AM EST
Filing Type: SC TO-T/A
Importance Score:
8
Sanofi Updates Dynavax Tender Offer with Regulatory Clearances and Shareholder Lawsuits
Price at Filing: $46.64
Real-time Price: $40.00 info
Change: -$6.64 (-14%) info
Market Cap: $95.459B info
Sentiment: Neutral
View Wiseek Article
SNY
Jan 23, 2026, 9:58 AM EST
Filing Type: 6-K
Importance Score:
7
Amlitelimab Phase 3 Studies Show Mixed Results in Atopic Dermatitis, Sanofi Plans Global Submissions
Price at Filing: $46.42
Real-time Price: $40.00 info
Change: -$6.42 (-14%) info
Market Cap: $95.459B info
Sentiment: Neutral
View Wiseek Article
SNY
Jan 16, 2026, 6:02 AM EST
Filing Type: 6-K
Importance Score:
8
Sanofi Secures EU Approval for Teizeild in Type 1 Diabetes, Plus Two China Approvals
Price at Filing: $45.52
Real-time Price: $40.00 info
Change: -$5.52 (-12%) info
Market Cap: $95.459B info
Sentiment: Positive
View Wiseek Article
SNY
Jan 12, 2026, 6:11 AM EST
Filing Type: SC TO-T
Importance Score:
10
Sanofi Commences Tender Offer to Acquire Dynavax Technologies for $15.50 Per Share in Cash
Price at Filing: $49.43
Real-time Price: $40.00 info
Change: -$9.43 (-19%) info
Market Cap: $95.459B info
Sentiment: Positive
View Wiseek Article
SNY
Jan 09, 2026, 6:09 AM EST
Filing Type: 6-K
Importance Score:
8
Sanofi's Tzield Receives US Priority Review for Expanded Use in Young Children with Type 1 Diabetes
Price at Filing: $48.53
Real-time Price: $40.00 info
Change: -$8.53 (-18%) info
Market Cap: $95.459B info
Sentiment: Positive
View Wiseek Article
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets